JO
ACET icon

John Overdeck’s Adicet Bio ACET Stock Holding History

John Overdeck’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$837K Buy
96,839
+53,733
+125% +$423K ﹤0.01% 3746
2026
Q1 		$294K Sell
43,106
-101,690
-70% -$761K ﹤0.01% 4087
2025
Q4 		$1.22M Buy
144,796
+91,385
+171% +$1.01M ﹤0.01% 2792
2025
Q3 		$692K Buy
53,411
+21,361
+67% +$252K ﹤0.01% 2816
2025
Q2 		$313K Buy
32,050
+1,114
+4% +$11.7K ﹤0.01% 2776
2025
Q1 		$374K Sell
30,936
-13,024
-30% -$186K ﹤0.01% 2633
2024
Q4 		$677K Sell
43,960
-4
-0% -$75 ﹤0.01% 2390
2024
Q3 		$1.01M Buy
43,964
+4,521
+11% +$101K ﹤0.01% 2115
2024
Q2 		$764K Buy
39,443
+6,845
+21% +$183K ﹤0.01% 2139
2024
Q1 		$1.23M Buy
32,598
+10,053
+45% +$416K ﹤0.01% 1822
2023
Q4 		$682K Buy
22,545
+8,463
+60% +$185K ﹤0.01% 2297
2023
Q3 		$309K Buy
14,082
+4,417
+46% +$156K ﹤0.01% 2481
2023
Q2 		$376K Buy
+9,665
New +$853K ﹤0.01% 2440
2022
Q4 		– Sell
-898
Closed -$204K – 2771
2022
Q3 		$204K Sell
898
-19,683
-96% -$5M ﹤0.01% 2096
2022
Q2 		$4.81M Sell
20,581
-3,969
-16% -$872K 0.02% 793
2022
Q1 		$7.84M Sell
24,550
-19,425
-44% -$4.47M 0.02% 703
2021
Q4 		$12.3M Buy
43,975
+39,137
+809% +$6.72M 0.03% 689
2021
Q3 		$607K Sell
4,838
-3,564
-42% -$442K ﹤0.01% 3067
2021
Q2 		$1.38M Buy
8,402
+1,999
+31% +$407K ﹤0.01% 2195
2021
Q1 		$1.34M Buy
6,403
+4,702
+276% +$1.08M ﹤0.01% 2049
2020
Q4 		$382K Buy
1,701
+1,062
+166% +$218K ﹤0.01% 2686
2020
Q3 		$122K Sell
639
-2,037
-76% -$515K ﹤0.01% 2918
2020
Q2 		$644K Buy
2,676
+67
+3% +$13.2K ﹤0.01% 1833
2020
Q1 		$301K Buy
2,609
+1,329
+104% +$197K ﹤0.01% 2299
2019
Q4 		$214K Buy
+1,280
New +$648K ﹤0.01% 3390

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

John Overdeck's ACET Position: Q2 2026 in Review

John Overdeck increased its Adicet Bio (ACET) stake by 125% in Q2 2026, buying an estimated $423K and bringing the position to 96,839 shares worth $837K. The position accounts for ﹤0.01% of the portfolio, ranked #3746.

John Overdeck first reported a position in ACET in Q4 2019 and has held it in 25 quarters since. The position peaked at $12.3M in Q4 2021. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • John Overdeck held 96,839 shares of Adicet Bio worth $837K as of Q2 2026.
  • John Overdeck bought 53,733 Adicet Bio shares in Q2 2026, an estimated $423K.
  • Adicet Bio made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3746 holding.
  • John Overdeck first reported a position in Adicet Bio in Q4 2019 and has held it in 25 quarters since.
  • John Overdeck's Adicet Bio position peaked at $12.3M in Q4 2021.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.